|
|
|
- Steven Robinson
- 5 years ago
- Views:
Transcription
1
2
3
4
5
6
7
8
9 THE OTHER 50% OF THE TDD PRANDIAL INSULIN ALISON B. EVERT, MS, RD, CDE BIBLIOGRAPHY Evidenced-Based Nutrition Recommendations and Guidelines: Academy of Nutrition and Dietetics: Type 1 and type 2 diabetes evidence-based nutrition practice guidelines for adults, Available from Accessed 5 June 2011 American Diabetes Association: Clinical practice recommendations: standards of medical care in diabetes: Diabetes Care 35 (Suppl. 1):S11 S63, 2012 American Diabetes Association: Nutrition recommendations and interventions for diabetes (Position Statement). Diabetes Care 31 (Suppl. 1):S61 S78, 2008 Franz MJ, Powers MA, Leontos C, Holmeister LA, Kulkarni K, Monk A, Wedel N, Gradwell E: The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. J Am Diet Assoc 110: , 2010 BASAL-BOLUS INSULIN THERAPY CARBOHYDRATE COUNTING Type 1: DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. BMJ 325: , 2002 Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: , 1993 Mühlhauser I, Jörgens V, Berger M, Graninger W, Gürlter W, Hornke L: Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia 25: , 1983 Casey D, Murphy K, Lawton J, White FF, Dineen S: A longitudinal qualitative study examining factors impacting on the ability of persons with T1DM to assimilate the Dose Adjustment of Normal Eating (DAFNE) principles into daily living and how these factors change over time. BMC Public Health 11:672, 2011 Lawton J, Rankin D, Cooke DD, Clark M, Elliot J, Heller S, UK NIHR DAFNE Study Group: Dose adjustment for normal eating: a qualitative longitudinal exploration of the food and eating practices of type 1 diabetes patients converted to flexible intensive insulin therapy in the UK. Diabetes Res Clin Pract 91:87 93, 2011 Rankin D, Cooke DD, Clark M, Hellert S, Elliott J, Lawton J: How and why to patients with type 1 diabetes sustain their use of flexible intensive insulin therapy? A qualitative longitudinal investigation of patients self-management practices following attendance at a Dose Adjustment for Normal Eating (DAFNE) course. Diabet Med 28: , 2011 Type 2: Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M: Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 31: , 2008
10 BOLUS CALCULATORS Gross TM, Kayne D, King A, Rother C, Juth S: A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther 5: , 2003 DOSING ALGORITHMS Davidson PC, Hebblewhite HR, Bode BW, Steed RD, Welch NS, Greenlee MC, Richardson PL, Johnson J: New evidence based guidelines for prescribing insulin by CSII (Abstract). Diabetes 51 (Suppl. 2):A128 A129, 2002 Davidson PC, Hebblewhite HR, Bode BW, Steed RD, Welch NS, Greenlee MC, Richardson PL, Johnson J: Statistically based CSII parameters: correction factor, CF (1700 Rule), carbohydrate-to-insulin ratio, CIR (2.8 Rule), and basal-to-total ratio. Diabetes Technol Ther 5:237, 2003 Davidson PC, Hebblewhite HR, Steed RD, Bode BW: Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 14: , 2008 Howorka K, Thoma H, Grillmayr H, Kitzler E: Phases of functional, near-normoglycaemic insulin substitution: what are computers good for in the rehabilitation process in type I (insulin-dependent) diabetes mellitus? Comput Methods Program Biomed 32: , 1990 Walsh J, Roberts R: Pumping Insulin. 2nd ed. San Diego, CA, Torrey Pines Press, 1994 Walsh J, Roberts R, Varma C, Bailey T: Using Insulin. San Diego, CA, Torrey Pines Press, 2003 CARBOHYDRATE COUNTING ESTIMATION AND RANGES Shapira G, Yodfat O, HaCohen A, Feigin P, Rubin R: Bolus guide: A novel insulin bolus Dosing decision support based on selection of carbohydrate ranges. J Diabetes Sci Technol 4: , 2010 Smart CE, Ross K, Edge JA, Collins CE, Colyvas K, King BR: Children and adolescents on intensive insulin therapy maintain postprandial glycaemic GLYCEMIC VARIABILITY & DYSGLYCEMIA Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295: , 2006 Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54: , 2005 Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106: , 2002 Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care 26: , 2003 INSULIN ANALOGS TIMING AND ACTION DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review: JAMA 289: , 2003 Hirsch IB: Insulin analogues. N Engl J Med 352: , 2005 Tridgell DM, Tridgell AH, Hirsch IB: Inpatient management of adults and children with type 1 diabetes. Endocrinol Metab Clin North Am 39: , 2010 Meal studies: Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, Chase PH: Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Tech 12: , 2010 Luijf YM, van Bon AC, Hoekstra JB, DeVries JH: Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 33: , 2010 Scaramuzza AE, Iafusco D, Santoro L, Bosetti A, De Palma A, Spiri D, Mameli C, Zuccotti GV: Timing of bolus in children with type 1 diabetes using continuous subcutaneous insulin infusion (TiBoDi Study). Diabetes Technol Tech 12: , 2010 INSULIN PUMP THERAPY EDUCATION & INTERVENTIONS Hirsch IB: Practical pearls in insulin pump therapy. Diab Technol Ther 12(Suppl 1):S23- S27, 2010
11 Schneiner G, Sobel RJ, Smith DE, Pick AJ, Kruger D, King J, Green K: Insulin pump therapy: guidelines for successful outcomes. Diabetes Educ 35(Suppl 2):S29-S49, 2009 VARIABLE BOLUS RESEARCH STUDIES OVERVIEW: Heinemann L: Insulin pump therapy: What is the evidence for using different types of boluses for coverage of prandial insulin requirements? J Diabetes Sci Technol 3: , 2009 NOVEL INSULIN DOSING ALGORITHMS Błazik M, Pańkowska E: The education of patients in prandial insulin dosing related to the structure of bolus calculators: Pediatr Endocrinol 16: , 2010 Blazik M, Szypowska A, Golicka D, Groele L, Pañkowska E: The Diabetics software in adjusting prandial insulin in patients treated with insulin pumps. The results of RCT study. Pediatr Diabetes 10(Suppl 11):71, 2009 Pańkowska, E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H: Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr 10:52-58, 2009a Pańkowska E, Szypowska A, Lipka M, Szpotañska M, Blazik M, Groele L: Application of novel dual wave meal bolus and its impact glycated hemoglobin A1C level in children with type 1 diabetes. Pediatr Diabetes 10: , 2009b Pańkowska E, Blazik M: Bolus calculator with nutrition database software, a new Concept of prandial insulin programming for pump users. J Diabetes Sci Technol 4: , 2010 Pańkowska E, Blazik M, Groele L: Does the fat-protein meal increase postprandial glucose levels in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther Online abstract ahead of print, October 20, 2011
Closing the loop, squaring the circle: Studies on insulin delivery, glucose monitoring and the artificial pancreas Luijf, Y.M.
UvA-DARE (Digital Academic Repository) Closing the loop, squaring the circle: Studies on insulin delivery, glucose monitoring and the artificial pancreas Luijf, Y.M. Link to publication Citation for published
Performance-powered. The OneTouch. Ping insulin pump and meter-remote.
Performance-powered. The OneTouch Ping insulin pump and meter-remote. I We don t just deliver insulin. We deliver outstanding clinical performance. P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 OneTouch Ping.
Do fat and protein affect post prandial glycemia in the outpatient real world setting? Neha Verma, MD Robert Melfi, MD
Do fat and protein affect post prandial glycemia in the outpatient real world setting? Neha Verma, MD Robert Melfi, MD Objectives Understand the effect of fat and protein on glycemic excursion in the post-prandial
A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal Glucose Control: Bolus Dosing
Journal of Diabetes Science and Technology Volume 1, Issue 1, January 2007 Diabetes Technology Society ORIGINAL ARTICLES A Prospective Evaluation of Insulin Dosing Recommendations in Patients with Type
INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
The Current Status of Bolus Calculator Decision-Support Software. Introduction. David C. Klonoff, M.D., FACP EDITORIAL
Journal of Diabetes Science and Technology Volume 6, Issue 5, September 2012 Diabetes Technology Society EDITORIAL The Current Status of Bolus Calculator Decision-Support Software David C., M.D., FACP
FACT SHEET TWO. The Evidence Base for DAFNE. The following is a list of relevant references:
FACT SHEET TWO The Evidence Base for DAFNE DAFNE has a solid evidence base. The programme has been developed over more than 25 years of rigorous research. [1, 2, 3, 4] This includes a randomised control
Application of novel dual wave meal bolus and its impact on glycated hemoglobin A1c level in children with type 1 diabetes
Pediatric Diabetes 2009: 10: 298 303 doi: 10.1111/j.1399-5448.2008.00471.x All rights reserved # 2008 The Authors Journal compilation # 2008 Blackwell Munksgaard Pediatric Diabetes Original Article Application
CGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117
CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current
Artificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
Basics of Insulin Pump Therapy Indications for using insulin pump therapy include one or more of the following 1 :
Advanced Insulin Pump Therapy By Micki Hall, MS, RD, LD, CDE, CPT Suggested CDR Learning Codes: 5190, 5400, 5410; Level 2 Suggested CDR Performance Indicators: 8.1.5, 8.3.6, 10.2.9 Basics of Insulin Pump
Diabetes Care 36: , 2013
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Both Dietary Protein and Fat Increase Postprandial Glucose Excursions in Children With Type 1 Diabetes, and the Effect
Making Sense of Glucose Monitoring. My Journey with Glucose Monitoring Over the Last 37 Years 8/7/2017
HSW1 Disclosure to Participants Making Sense of Glucose Monitoring Alison B. Evert, MS, RD, CDE UW Neighborhood Clinics UW Medicine Seattle, WA Conflict of Interest (COI) and Financial Relationship Disclosures:
Interpretation of Continuous Glucose Monitoring (CGM) Data
Interpretation of Continuous Glucose Monitoring (CGM) Data Sherri Horvat, BSN, RN, CDE Blood Glucose Manager, Animas Corporation A Johnson & Johnson Diabetes Care Company Overview of CGM Continuous glucose
International Journal of Scientific & Engineering Research Volume 8, Issue 5, May ISSN
International Journal of Scientific & Engineering Research Volume 8, Issue 5, May-2017 58 SMARTPHONE BASED INSULIN RECOMMENDATION FOR TYPE1 DIABETES 1 Keerthanaa R, 2 Dr. K. Kumar 1 PG Scholar, 2 Assistant
Clinical Evidence for Insulin Pump Therapy
Clinical Evidence for Insulin Pump Therapy 9501169-011 Objective Review the clinical evidence supporting the use of insulin pump therapy Key Points The benefits of CSII are: Improved metabolic control
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
Clinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
1. What s the point of a network the case for research? 2. How to use CSII effectively
1. What s the point of a network the case for research? 2. How to use CSII effectively John Pickup King s College London Faculty of Medicine Guy s Hospital, London What should an insulin pump network do?
Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type 1 Diabetes Mellitus
DIABETES TECHNOLOGY & THERAPEUTICS Volume 14, Number 5, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2011.0184 Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type
EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK. Optimising Glycaemic Control for Children and Young People with Diabetes
EAST OF ENGLAND CHILDREN AND YOUNG PEOPLE S DIABETES NETWORK Optimising Glycaemic Control for Children and Young People with Diabetes Local diabetes teams need to take on the responsibility of ensuring
Counting the Carbs, Fat and Protein in Type 1 Diabetes Translating the Research into Clinical Practice
Welcome to Allied Health Telehealth Virtual Education Counting the Carbs, Fats and Protein in Type 1 Diabetes Translating the Research into Clinical Practice Dr Carmel Smart, PhD Senior Specialist Paediatric
Rapid-acting and Regular Insulin are Equal for High Fat-Protein Meal in Individuals with Type 1 Diabetes Treated with Multiple Daily Injections
Diabetes Ther (2018) 9:339 348 https://doi.org/10.1007/s13300-017-0364-2 ORIGINAL RESEARCH Rapid-acting and Regular Insulin are Equal for High Fat-Protein Meal in Individuals with Type 1 Diabetes Treated
Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
The next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
Glycemic Variability:
Glycemic Variability: Do the Differences Make a Difference? Kim L Kelly, PharmD, BCPS, FCCP Define Variability VERY LOW GLYCEMIC VARIABILITY LOW GLYCEMIC VARIABILITY HIGH GLYCEMIC VARIABILITY So what s
Advances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
Factors associated with basal insulin dose in Japanese children and young adult type 1 diabetics
ORIGINAL ARTICLE Factors associated with basal insulin dose in Japanese children and young adult type 1 diabetics Tomomi Hashimoto 1, Tomoyuki Kawamura 1 *, Yoneo Kashihara 1, Masakazu Hirose 1, Takashi
PREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM
66 PREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM SHOKOUFEH BONAKDARAN, REZA RAJABIAN ABSTRACT BACKGROUND:
Carbohydrate Counting In Type 1 Diabetes: What Do We Know?
Carbohydrate Counting In Type 1 Diabetes: What Do We Know? Gail Spiegel, MS RD CDE Barbara Davis Center for Childhood Diabetes Keystone, CO July 2012 Outline Why Count Carbs? Carb counting intervention
Non-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
Advances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
Update on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
Insulin Pump Therapy for Type 2
9501172-011 Insulin Pump Therapy for Type 2 Objective To show the effectiveness of CSII for insulin-taking type 2 patients Key Points Tight glycemic control decreases risk of diabetes-related complications
4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures
Flexible Intensive Insulin Therapy (FIIT) in People with Type Diabetes: A Viable Option Kim Bisanz, MFCS, RDN, LDN, CDE Minnesota Academy of Nutrition & Dietetics Annual Meeting April 19, 18 18 MFMER slide-1
April Dear (Editor):
April 2014 Dear (Editor): Registered Dietitians (RD) play an integral role in patient care in the medical intensive care unit. RD s have increased knowledge in blood glucose control and reducing adverse
1.* Dosage/Administration
Pramlintide (Symlin ) [Developed, February 2006; Revised, May 2006; January 2010; December 2011; October 2013] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Information on indications for use or
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
Limitations of Conventional Methods of Self-Monitoring of Blood Glucose
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Limitations of Conventional Methods of Self-Monitoring of Blood Glucose Lessons learned from 3 days of continuous glucose sensing in pediatric
UKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
Advances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
Abstract CLINICAL APPLICATIONS. Objectives: Methods: Results: Conclusion: Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Volume 1, Issue 3, May 2007 Diabetes Technology Society CLINICAL APPLICATIONS Combined Insulin Pump Therapy with Real-Time Continuous Glucose Monitoring Significantly
DAFNE (Dose Adjustment For Normal Eating)
DAFNE (Dose Adjustment For Normal Eating) Promoting the Expert Patient Professor David McIntyre Mater Health Services and University of Queensland Brisbane AUSTRALIA DAFNE and OzDAFNE Outline Context of
By Betsy B. Dokken, PhD, NP, CDE. Keywords: diabetes mellitus, insulin analogues, insulin therapy
How insulin analogues can benefit patients Abstract: Primary care providers offer diabetes care for many patients in the United States. Primary care nurse practitioners can benefit from an understanding
Basal Prandial Insulin Delivery in Type 2 Diabetes Mellitus via the V-Go : A Novel Continuous Subcutaneous Infusion Device
Journal of Diabetes Science and Technology Volume 2, Issue 1, January 2008 Diabetes Technology Society ORIGINAL ARTICLES Basal Prandial Insulin Delivery in Type 2 Diabetes Mellitus via the V-Go : A Novel
Ensuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes
Ensuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes FACULTY ADVISOR Lori Laffel, MD, MPH Professor, Pediatrics Harvard Medical School Chief, Pediatric, Adolescent and Young
Angela Girelli e Giorgio Grassi. Stato dell arte del paziente in SAP Ipoglicemia e variabilità glicemica
Angela Girelli e Giorgio Grassi Stato dell arte del paziente in SAP Ipoglicemia e variabilità glicemica Le basi sperimentali Glycemia Ceriello A:Diabetes 2008: 57: 1349 1354 17.50 15.50 Glycemia (mmol/l)
Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
MTE 4 and 9 Macronutrient Mix: Ideal Intake vs. Real-World Eating? References:
MTE 4 and 9 Macronutrient Mix: Ideal Intake vs. Real-World Eating? Bayview Room, Bay Level Marion J. Franz, MS, RDN, CDE Saturday, March 5, 2016 2:00 p.m. 3:30 p.m. and 3:45 p.m. 5:15 p.m. Research trials
Faculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care
C H A P T E R 41 Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care K Chaithanya Murthy, B Ramya, E Vidya, RM Anjana, V Mohan ABSTRACT Over the past decades, several newer technologies have
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
SUPPLEMENTARY DATA. Supplementary Figure 1. Flow diagram of study selection
Supplementary Figure 1. Flow diagram of study selection Supplementary Table 1. Summary of included studies examining the effects of fat, protein and on postprandial glycemia in type 1 diabetes Evidence
Norbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article
524105DSTXXX10.1177/1932296814524105Journal of Diabetes Science and TechnologyHermanns et al research-article2014 Original Article The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose
Take Charge Feel Positive About Nutrition. Marion J. Franz, MS, RD, CDE
Take Charge Feel Positive About Nutrition Marion J. Franz, MS, RD, CDE Questions What questions do you have? What s important? What s controversial? How important is weight loss? What about physical activity?
Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
Diabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
Clinical Performance of a Device That Applies Local Heat to the Insulin Infusion Site: A Crossover Study
Journal of Diabetes Science and Technology Volume 6, Issue 2, March 2012 Diabetes Technology Society ORIGINAL ARTICLE Clinical Performance of a Device That Applies Local Heat to the Insulin Infusion Site:
UNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE
UNCOVERING THE BENEFITS OF THE ACCU- CHEK BOLUS ADVISOR MICHAEL PORTER CDE 1 LEARNING OBJECTIVES By the end of this session participants should be able to understand: The benefits of bolus advisors The
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
Diabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
Recommendations for Using Real-Time Continuous Glucose Monitoring (rtcgm) Data for Insulin Adjustments in Type 1 Diabetes
663747DSTXXX10.1177/1932296816663747Journal of Diabetes Science and TechnologyPettus and Edelman review-article2016 Review Article Recommendations for Using Real-Time Continuous Glucose Monitoring (rtcgm)
Diabetes Research at Nemours Jacksonville
Diabetes Research at Nemours Jacksonville Larry A. Fox, M.D. Nemours Children s Clinic Jacksonville, FL Medical Director, NE Florida Pediatric Diabetes Center Assoc. Professor of Pediatrics, Mayo College
HAP PA-HEN Achieving More Together
HAP PA-HEN Achieving More Together Managing Hyperglycemia in the Hospital: Strategies for Safe and Effective Care Pennsylvania Patient Safety Authority Managing Hyperglycemia in the Hospital: Strategies
Initiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
Original Article. Allen B. King, MD; Dawn Clark, ANP ABSTRACT
Original Article Allen B. King, MD; Dawn Clark, ANP ABSTRACT Objective: To assess hypoglycemia caused by eating the last meal of the day earlier or its omission in well controlled type 2 diabetes mellitus
Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
Insulin Intensification: A Patient-Centered Approach
MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director
The hallmark of type 2 diabetes mellitus (T2DM) is progressive
16 SUPPLEMENT TO JAPI january 2013 VOL. 61 Original Article Initiating Therapy or Switching to Biphasic Insulin Aspart Improves Glycaemic Control in Type 2 Diabetes: An Indian Experience from the A 1 chieve
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
Sanofi U.S. Medical Affairs Request for Proposal
Sanofi U.S. Medical Affairs Request for Proposal Date: July 23 rd, 2015 Disease State: Diabetes Therapeutic Area: Diabetes Area of Interest: Post-prandial glucose control for current basal insulin patients
APPLICATION OF INSULIN PUMP IN THE TREATMENT OF DIABETES MELLITUS
APPLICATION OF INSULIN PUMP IN THE TREATMENT OF DIABETES MELLITUS Dr. Dwarika Pradhan 1*, Prof. Zeng Jiao-E 2, Dr. Zhong Wen 3, Prof. Du Ai Min 4, Dr. Pankaj Poudel 5 and Dr. Farahan Khan 6 1,2,3,4,5,6
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
Exercise Prescription in Type 1 Diabetes
Exercise Prescription in Type 1 Diabetes Michael Riddell, PhD Professor, Muscle Health Research Centre and School of Kinesiology & Health Science, York University Senior Scientist, LMC Diabetes & Endocrinology,
Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
Insulin Pumps - External
Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of
Do women have to come off DAFNE when pregnant?
Do women have to come off DAFNE when pregnant? Dr Helen R Murphy hm386@medschl.cam.ac.uk DAFNE Manchester June 26 2015 Topics for discussion Current practice in T1D pregnancy Reflect on current DAFNE guidelines
Disclosures. Glycemic Control in the Intensive Care Unit. Objectives. Hyperglycemia. Hyperglycemia. History. No disclosures
Disclosures Glycemic Control in the Intensive Care Unit No disclosures Jorie Frasiolas, Pharm.D., BCPS Clinical Pharmacy Manager, CTICU NewYork-Presbyterian Hospital Columbia University Medical Center
Insulin-Pump Therapy for Type 1 Diabetes Mellitus
T h e n e w e ngl a nd j o u r na l o f m e dic i n e clinical therapeutics Insulin-Pump Therapy for Type 1 Diabetes Mellitus John C. Pickup, B.M., D.Phil. This Journal feature begins with a case vignette
5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
APPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
Comparing the Efficacy, Safety, and Utility of Intensive Insulin Algorithms for a Primary Care Practice
Diabetes Ther (2011) 2(1):40-50. DOI 10.1007/s13300-010-0014-4 REVIEW Comparing the Efficacy, Safety, and Utility of Intensive Insulin Algorithms for a Primary Care Practice Jeff Unger Received: December
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
Timely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
Harvesting Healthy Hemogobins: Optimal Management of A1c and Beyond. Carol H. Wysham, M.D Rockwood Clinic Spokane, WA
Harvesting Healthy Hemogobins: Optimal Management of A1c and Beyond Carol H. Wysham, M.D Rockwood Clinic Spokane, WA Diabetes: 21 Million and Climbing Estimated 15 million diagnosed + 6.2 million undiagnosed
Application of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
Personal statement on Continuous Subcutaneous Insulin Infusion Professor John Pickup
1 Personal statement on Continuous Subcutaneous Insulin Infusion Professor John Pickup King s College London School of Medicine, Guy s Hospital, London SE1 9RT Experience of the technology I am the lead
Pump Therapy - Simple, Proven, and Well Accepted
Pump Therapy - Simple, Proven, and Well Accepted Innovating for life. Pump therapy is simple for providers and patients Healthcare Providers Simple outpatient procedure: Low burden and cost to transition
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
Glycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
Macronutrients and Dietary Patterns for Glucose Control
제 20 회대한당뇨병학회춘계학술대회 Macronutrients and Dietary Patterns for Glucose Control 2017.5.13 서울대학교병원임정현 Conflict of interest disclosure None Committee of Scientific Affairs Contents Review of Nutrition Recommendation
Initiating and Titrating Insulin in Patients With Type 2 Diabetes
Initiating and Titrating Insulin in Patients With Type 2 Diabetes Joseph A. Henske, MD, Michelle L. Griffith, MD, and Michael J. Fowler, MD Case Presentation A 48-year-old African-American man presents
Dr. Yash Pal Munjal MD, FICP, MAMS, FRCP (EDIN), FACP (USA) FIACM, FIAMS, FIMSA
Dr. Yash Pal Munjal MD, FICP, MAMS, FRCP (EDIN), FACP (USA) FIACM, FIAMS, FIMSA Medical Director, Banarsidas Chandiwala Institute of Medical Sciences Chief Consultant, Centre for Diabetes & Lifestyle Diseases,
Continuous subcutaneous insulin infusion vs. multiple daily injections
Cent. Eur. J. Med. 6(5) 2011 575-581 DOI: 10.2478/s11536-011-0064-7 Central European Journal of Medicine Continuous subcutaneous insulin infusion Saša P. Radenković 1,2*, Milica M. Pešić 1,2, Milena D.
POLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP071 Section: Medical Benefit Policy Subject: Continuous Subcutaneous Glucose Monitor CSGM I. Policy: Continuous Subcutaneous Glucose Monitor (CSGM) II. Purpose/Objective: